Therefore, this study aimed to identify the subpopulations who could benefit most from folic acid treatment in reducing the first stroke risk through simultaneous consideration of MTHFR C677T genotypes and platelet activation parameters in hypertensive patients. This evidence concerns the gene MTHFR and stroke disorder.